

DECISION OF THE ATHLETICS INTEGRITY UNIT IN THE CASE OF MR MARK KANGOGO

INTRODUCTION

1. World Athletics has established the Athletics Integrity Unit ("**AIU**") whose role is to protect the integrity of the sport of Athletics, including fulfilling World Athletics' obligations as a Signatory to the World Anti-Doping Code ("the "**Code**"). World Athletics has delegated implementation of the World Athletics Anti-Doping Rules ("**ADR**") to the AIU, including but not limited to the following activities in relation to International-Level Athletes: Testing, Investigations, Results Management, Hearings, Sanctions and Appeals.
2. Mr Mark Kangogo ("the **Athlete**") is a 33-year-old road and mountain runner from Kenya¹.
3. This decision is issued by the AIU pursuant to Rule 8.5.6 ADR, which provides as follows:

"8.5.6 In the event that the Athlete or other Person either (i) admits the violation and accepts the proposed Consequences or (ii) is deemed to have admitted the violation and accepted the Consequences as per Rule 8.5.2(f), the Integrity Unit will promptly:

- (a) issue a decision confirming the commission of the violation(s) and the imposition of the specified Consequences (including, if applicable, a justification for why the maximum potential sanction was not imposed);*
- (b) Publicly Report that decision in accordance with Rule 14;*
- (c) send a copy of the decision to the Athlete or other Person and to any other party that has a right, further to Rule 13, to appeal the decision (and any such party may, within 15 days of receipt, request a copy of the full case file pertaining to the decision)."*

THE ATHLETE'S COMMISSION OF ANTI-DOPING RULE VIOLATIONS

4. Rule 2 ADR sets out that the following shall constitute an Anti-Doping Rule Violation:
 - "2.1 Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete's Sample*

[...]
 - 2.2 Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method"*
5. On 13 August 2022, the Athlete provided a urine Sample In-Competition at the 'Sierre-Zinal WMRA World Cup race' held in Switzerland, which was given code 3628896 (the "**Sample**").

¹ <https://www.worldathletics.org/athletes/kenya/mark-kibiwott-kangogo-14639530>

6. On 5 September 2022, the World Anti-Doping Agency (“WADA”) accredited laboratory in Lausanne, Switzerland (the “Laboratory”) reported an Adverse Analytical Finding in the Sample based on the presence of 19-Norandrosterone (“Norandrosterone”)² greater than 15ng/mL³ and Triamcinolone Acetonide (together, the “Adverse Analytical Finding”).
7. The AIU reviewed the Adverse Analytical Finding in accordance with Article 5 of the International Standard for Results Management (“ISRM”) and determined that:
 - 7.1. the Athlete did not have a Therapeutic Use Exemption (“TUE”) that had been granted (or that would be granted) for the Norandrosterone or Triamcinolone Acetonide substances found in the Sample; and
 - 7.2. there was no apparent departure from the International Standard for Testing and Investigations (“ISTI”) or from the International Standard for Laboratories (“ISL”) that could reasonably have caused the Adverse Analytical Finding.
8. Therefore, on 9 September 2022, the AIU notified the Athlete of the Adverse Analytical Finding in accordance with Article 5.1.2.1 of the ISRM, including that the Adverse Analytical Finding may result in Anti-Doping Rule Violations pursuant to Rule 2.1 ADR and/or Rule 2.2 ADR and of the imposition of an immediate Provisional Suspension.
9. The Athlete was also informed of his rights, *inter alia*, to request the B Sample analysis, to request copies of the laboratory documentation supporting the Adverse Analytical Finding and to admit the Anti-Doping Rule Violations and potentially benefit from a one-year reduction in the period of Ineligibility pursuant to Rule 10.8.1 ADR.
10. On 9 and 14 September 2022, the Athlete wrote to the AIU with the list of supplements and medications that he said he had used to treat an ankle injury prior to the doping control. However, none of them listed Norandrosterone or Triamcinolone Acetonide in their ingredients.
11. On 10 October 2022, the AIU interviewed the Athlete in relation to the Adverse Analytical Finding.
12. On the same day, the AIU received an Admission of Anti-Doping Rule Violation and Acceptance of Consequences Form signed by the Athlete.

CONSEQUENCES

13. This is the Athlete’s first Anti-Doping Rule Violation.
14. Rule 10.2 ADR specifies that the period of Ineligibility for an Anti-Doping Rule Violation under Rule 2.1 or Rule 2.2 shall be as follows:

“10.2.1 *Save where Rule 10.2.4 applies, the period of Ineligibility will be four years where:*

² Norandrosterone is a metabolite of nandrolone or nandrolone precursors. 19-noretiocholanolone was also identified in the Sample.

³ See WADA technical document TD2021NA (section 4.3).

- (a) *The anti-doping rule violation does not involve a Specified Substance or a Specified Method, unless the Athlete or other Person can establish that the anti-doping rule violation was not intentional.*
- (b) *The anti-doping rule violation involves a Specified Substance or a Specified Method and the Integrity Unit can establish that the anti-doping rule violation was intentional.”*
15. Norandrosterone is a Prohibited Substance under the WADA 2022 Prohibited List under the category S1.1 Anabolic Androgenic Steroids (AAS). It is a Non-Specified Substance prohibited at all times.
16. Triamcinolone acetonide is a Prohibited Substance under the WADA 2022 Prohibited List under the category S9: *Glucocorticoids*. It is a Specified Substance prohibited In-Competition when administered by any injectable, oral⁴ or rectal route.
17. The period of Ineligibility to be imposed is therefore a period of four (4) years, unless the Athlete demonstrates that the Anti-Doping Rule Violations were not intentional⁵.
18. The Athlete has not demonstrated that the Anti-Doping Rule Violations were not intentional. Therefore, the mandatory period of Ineligibility is a period of Ineligibility of four (4) years.
19. However, Rule 10.8.1 ADR provides that an athlete potentially subject to an asserted period of Ineligibility of four (4) years may benefit from a one (1)-year reduction in the period of Ineligibility based on an early admission and acceptance of sanction:
- “10.8.1 One year reduction for certain anti-doping rule violations based on early admission and acceptance of sanction.*
- Where the Integrity Unit notifies an Athlete or other Person of an anti-doping rule violation charge that carries an asserted period of Ineligibility of four (4) or more years (including any period of Ineligibility asserted under Rule 10.4), if the Athlete or other Person admits the violation and accepts the asserted period of Ineligibility no later than 20 days after receiving the Notice of Charge, the Athlete or other Person may receive a one (1) year reduction in the period of Ineligibility asserted by the Integrity Unit. Where the Athlete or other Person receives the one (1) year reduction in the asserted period of Ineligibility under this Rule 10.8.1, no further reduction in the asserted period of Ineligibility will be allowed under any other Rule.”*
20. The Athlete was notified of the Adverse Analytical Finding and that this may result in Anti-Doping Rule Violations under Rule 2.1 and/or Rule 2.2 and a period of Ineligibility of four (4) years on 9 September 2022⁶.

⁴ Including oromucosal (e.g. buccal, gingival, sublingual).

⁵ The mandatory period of Ineligibility in relation to an Adverse Analytical Finding is four (4) years for a Non-Specified Substance (i.e. Norandrosterone) and two (2) years for a Specified Substance (i.e. Triamcinolone acetonide). In accordance with Rule 10.9.3(a), since both substances were found in the same Sample, these violations will be considered together as a single first violation and the more severe sanction of the two will apply, apply i.e., four (4) years.

⁶ This Notice of Allegation of Anti-Doping Rule Violations was issued to the Athlete in accordance with Article 5.1.2 of the ISRM, prior to a Notice of Charge issued in accordance with Article 7 of the ISRM. Considering the Athlete’s admission and acceptance of Consequences on 10 October 2022, no Notice of Charge was ever issued.

21. On 10 October 2022, the Athlete returned a signed Admission of Anti-Doping Rule Violations and Acceptance of Consequences Form confirming that he admitted the Anti-Doping Rule Violations and accepted the asserted period of Ineligibility.
22. The Athlete shall therefore receive a one (1) year reduction in the asserted period of Ineligibility pursuant to Rule 10.8.1 based on an early admission and acceptance of sanction.
23. On the basis that the Athlete has admitted the Anti-Doping Rule Violations under Rule 2.1 ADR and Rule 2.2 ADR, in accordance with Rule 10.2.1 ADR and the application of Rule 10.8.1 ADR, the AIU confirms by this decision the following Consequences for a first Anti-Doping Rule Violation:
 - 23.1. a period of Ineligibility of three (3) years commencing on 9 September 2022 (the date of Provisional Suspension); and
 - 23.2. disqualification of the Athlete's results since and including 13 August 2022, with all resulting Consequences, including the forfeiture of any titles, awards, medals, points prizes and appearance money.
24. The Athlete has accepted the above Consequences for his Anti-Doping Rule Violations and has expressly waived his right to have those Consequences determined by the Disciplinary Tribunal at a hearing.

PUBLICATION

25. In accordance with Rule 8.5.6(b) ADR, the AIU shall publicly report this decision on the AIU's website.

RIGHTS OF APPEAL

26. This decision constitutes the final decision of the AIU pursuant to Rule 8.5.6 ADR.
27. Further to Rule 13.2.3 ADR, WADA and the Anti-Doping Agency of Kenya ("**ADAK**") have a right of appeal against this decision to the Court of Arbitration for Sport in Lausanne, Switzerland, in accordance with the procedure set out at Rule 13.6.1 ADR.
28. If an appeal is filed against this decision by WADA or ADAK, the Athlete will be entitled to exercise his right of cross-appeal in accordance with Rule 13.2.4 ADR.

Monaco, 12 October 2022